Alain A. Mina

Hematology
3800 Reservoir Rd NW
Washington, DC 20007

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications

Treatment inequity among older adults with newly diagnosed acute myeloid leukemia ineligible for intensive therapy.

Treatment inequity among older adults with newly diagnosed acute myeloid leukemia ineligible for intensive therapy.

Journal: Leukemia & lymphoma
Published: July 12, 2026

Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis.

Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis.

Journal: Leukemia & lymphoma
Published: June 07, 2026

Targeting the IL-8 axis in high-risk myelodysplastic syndromes: a clinical experience with antibody blockade combined with decitabine/cedazuridine.

Targeting the IL-8 axis in high-risk myelodysplastic syndromes: a clinical experience with antibody blockade combined with decitabine/cedazuridine.

Journal: Leukemia & lymphoma
Published: April 28, 2026

Pharmacologic progress in higher-risk MDS: an uphill battle.

Pharmacologic progress in higher-risk MDS: an uphill battle.

Journal: Expert opinion on pharmacotherapy
Published: March 10, 2026

A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions.

A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions.

Journal: Nature reviews. Clinical oncology
Published: March 10, 2026

Desmosine as a Novel Biomarker Candidate for Pulmonary and Cutaneous Chronic Graft-versus-Host Disease.

Desmosine as a Novel Biomarker Candidate for Pulmonary and Cutaneous Chronic Graft-versus-Host Disease.

Journal: Transplantation and cellular therapy
Published: February 23, 2026

Desmosine as a Novel Biomarker Candidate for Pulmonary and Cutaneous Chronic Graft-Versus-Host Disease.

Desmosine as a Novel Biomarker Candidate for Pulmonary and Cutaneous Chronic Graft-Versus-Host Disease.

Journal: Transplantation and cellular therapy
Published: February 23, 2026

Acute myeloid leukemia after myeloproliferative neoplasms: Real-world outcomes in the new treatment era in the United States.

Acute myeloid leukemia after myeloproliferative neoplasms: Real-world outcomes in the new treatment era in the United States.

Journal: Cancer
Published: January 21, 2026

Targeting metabolism in acute myeloid leukemia: the next therapeutic frontier?

Targeting metabolism in acute myeloid leukemia: the next therapeutic frontier?

Journal: Chinese clinical oncology
Published: December 30, 2025

Facing Death.

Facing Death.

Journal: JCO oncology practice
Published: December 11, 2025

Luspatercept for patients with lower-risk myelodysplastic syndromes/neoplasms: a systematic review and meta-analysis.

Luspatercept for patients with lower-risk myelodysplastic syndromes/neoplasms: a systematic review and meta-analysis.

Journal: Blood advances
Published: July 08, 2025

Iron chelation therapy in myelodysplastic syndromes and allogeneic hematopoietic cell transplantation, a delicate balance.

Iron chelation therapy in myelodysplastic syndromes and allogeneic hematopoietic cell transplantation, a delicate balance.

Journal: Blood reviews
Published: May 09, 2025
Showing 1-12 of 54

Last Updated: 09/26/2026